News4 mins ago
Annovis Bio Announces Completion of Phase III Parkinson’s Disease Treatment Enrollment at Record Pace
BERWYN, Pa., June 8, 2023 /PRNewswire/ — Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company addressing neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s...
